Panagora Asset Management’s Immune Design Corp. IMDZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-224,038
| Closed | -$1.31M | – | 2775 |
|
|
2019
Q1 | $1.31M | Sell |
224,038
-257,991
| -54% | -$879K | 0.01% | 1019 |
|
|
2018
Q4 | $627K | Buy |
482,029
+97,407
| +25% | +$169K | ﹤0.01% | 1265 |
|
|
2018
Q3 | $1.33M | Sell |
384,622
-23,445
| -6% | -$88K | 0.01% | 1010 |
|
|
2018
Q2 | $1.86M | Buy |
408,067
+14,120
| +4% | +$56.2K | 0.01% | 907 |
|
|
2018
Q1 | $1.3M | Buy |
393,947
+28,024
| +8% | +$99.2K | 0.01% | 1056 |
|
|
2017
Q4 | $1.43M | Buy |
365,923
+166,997
| +84% | +$910K | 0.01% | 1012 |
|
|
2017
Q3 | $2.06M | Sell |
198,926
-11,771
| -6% | -$116K | 0.01% | 845 |
|
|
2017
Q2 | $2.05M | Buy |
210,697
+70,734
| +51% | +$496K | 0.01% | 846 |
|
|
2017
Q1 | $952K | Buy |
139,963
+16,128
| +13% | +$93.2K | ﹤0.01% | 1159 |
|
|
2016
Q4 | $681K | Buy |
123,835
+39,250
| +46% | +$277K | ﹤0.01% | 1347 |
|
|
2016
Q3 | $641K | Sell |
84,585
-12,059
| -12% | -$88.2K | ﹤0.01% | 1355 |
|
|
2016
Q2 | $789K | Buy |
96,644
+7,190
| +8% | +$89.7K | ﹤0.01% | 1212 |
|
|
2016
Q1 | $1.16M | Buy |
89,454
+17,946
| +25% | +$207K | 0.01% | 1041 |
|
|
2015
Q4 | $1.44M | Buy |
71,508
+1,539
| +2% | +$26.5K | 0.01% | 930 |
|
|
2015
Q3 | $854K | Buy |
69,969
+66,747
| +2,072% | +$1.25M | ﹤0.01% | 1102 |
|
|
2015
Q2 | $67K | Buy |
+3,222
| New | +$76.1K | ﹤0.01% | 2067 |
|
Panagora Asset Management's IMDZ Position: Q2 2019 in Review
Panagora Asset Management sold out of Immune Design Corp. (IMDZ) in Q2 2019, closing a stake of 224,038 shares — an estimated $1.31M sold.
Panagora Asset Management first reported a position in IMDZ in Q2 2015 and held it in 16 quarters. The position peaked at $2.06M in Q3 2017. 0 funds tracked by Wall St. Rank hold IMDZ as of Q2 2019.
- Panagora Asset Management reported no remaining Immune Design Corp. position as of Q2 2019 after selling out during the quarter.
- Panagora Asset Management sold 224,038 Immune Design Corp. shares in Q2 2019, an estimated $1.31M.
- Panagora Asset Management first reported a position in Immune Design Corp. in Q2 2015 and held it in 16 quarters.
- Panagora Asset Management's Immune Design Corp. position peaked at $2.06M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Immune Design Corp. as of Q2 2019.
Based on Panagora Asset Management's 13F filing for Q2 2019, filed 9 Aug 2019.